首页> 外文期刊>Biochemistry and Biophysics Reports >Selective depletion of basophils ameliorates immunoglobulin E-mediated anaphylaxis
【24h】

Selective depletion of basophils ameliorates immunoglobulin E-mediated anaphylaxis

机译:嗜碱性粒细胞的选择性消耗可改善免疫球蛋白E介导的过敏反应

获取原文
           

摘要

Basophils, which are the rarest granulocytes, play crucial roles in protective immunity against parasites and development of allergic disorders. Although immunoglobulin (Ig)E-dependent responses via receptor for IgE (FcεRI) in basophils have been extensively studied, little is known about cell surface molecules that are selectively expressed on this cell subset to utilize the elimination in vivo through treatment with monoclonal antibody (mAb). Since CD200 receptor 3 (CD200R3) was exclusively expressed on basophils and mast cells (MCs) using a microarray screening, we have generated anti-CD200R3 mAb recognizing CD200R3A. In this study we examined the expression pattern of CD200R3A on leukocytes, and the influence of the elimination of basophils by anti-CD200R3A mAb on allergic responses. Flow cytometric analysis showed that CD200R3A was primarily expressed on basophils and MCs, but not on other leukocytes. Administration with anti-CD200R3A mAb led to the prominent specific depletion of tissue-resident and circulating basophils, but not MCs. Furthermore, in vivo depletion of basophils ameliorated IgE-mediated systemic and local anaphylaxis. Taken together, these findings suggest that CD200R3A is reliable cell surface marker for basophils in vivo , and targeting this unique molecule with mAb for the elimination of basophils may serve as a novel therapeutic strategy in ameliorating the allergic diseases. Highlights ? CD200R3A was primarily expressed on basophils and mast cells. ? Administration with anti-CD200R3A mAb depleted basophils, but not MCs. ? Depletion of basophils by anti-CD200R3A mAb ameliorated IgE-mediated systemic and local anaphylaxis.
机译:嗜碱性粒细胞是最稀有的粒细胞,在针对寄生虫和过敏性疾病发展的保护性免疫中起着至关重要的作用。尽管已经广泛研究了嗜碱性粒细胞中通过IgE(FcεRI)受体产生的免疫球蛋白(Ig)E依赖性应答,但对在该细胞亚群上选择性表达以利用单克隆抗体治疗体内消除作用的细胞表面分子知之甚少( mAb)。由于使用微阵列筛选技术仅在嗜碱性粒细胞和肥大细胞(MC)上表达CD200受体3(CD200R3),所以我们已经产生了识别CD200R3A的抗CD200R3 mAb。在这项研究中,我们研究了CD200R3A在白细胞上的表达模式,以及抗CD200R3A mAb消除嗜碱性粒细胞对变态反应的影响。流式细胞仪分析表明CD200R3A主要在嗜碱性粒细胞和MCs上表达,但在其他白细胞上不表达。用抗CD200R3A mAb给药会导致组织驻留和循环中的嗜碱粒细胞(而非MC)的显着特异性消耗。此外,嗜碱性粒细胞的体内消耗改善了IgE介导的全身和局部过敏反应。综上所述,这些发现表明CD200R3A是体内嗜碱性粒细胞的可靠细胞表面标记,并且以mAb靶向这种独特的分子以消除嗜碱性粒细胞可以作为减轻过敏性疾病的新治疗策略。强调 ? CD200R3A主要在嗜碱性粒细胞和肥大细胞上表达。 ?用抗CD200R3A mAb的嗜碱性粒细胞给药,但不使用MC。 ?抗CD200R3A mAb消耗嗜碱性粒细胞可改善IgE介导的全身和局部过敏反应。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号